Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781717 | 0.82 | POLB (0.55) | TP53ALDH1A1ATMKDM4ELMNA | |
| SCHEMBL1781126 | 0.80 | TSHR (0.58) | TP53ALDH1A1ATMLMNAMAPT | |
| SCHEMBL1783515 | 0.76 | TP53 (0.46) | TP53ATMKDM4ELMNAMAPT | |
| SCHEMBL2288883 | 0.74 | TRPA1 (0.57) | TRPA1TRPV1ALDH1A1GAAATM | |
| SCHEMBL27814536 | 0.74 | TRPV1 (0.60) | TRPA1TRPV1ALDH1A1GAAATM | |
| SCHEMBL10457573 | 0.72 | GAA (0.64) | TRPA1TRPV1GAAATM | |
| SCHEMBL4380655 | 0.71 | TRPV1 (0.54) | TRPA1TRPV1ALDH1A1 | |
| SCHEMBL12655782 | 0.71 | ALDH1A1 (0.66) | TRPA1TRPV1ALDH1A1GAAKDM4E | |
| Hydrochloric Acid SCHEMBL4380652 | 0.70 | HRH3 (0.54) | TRPA1TRPV1ALDH1A1 | |
| SCHEMBL8094577 | 0.69 | TRPA1 (0.54) | TRPA1TRPV1ALDH1A1GAAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | UNG, TYMS, UMPS | TRPA1 4595/4885TRPV1 4104/4885TP53 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.